Capricor Therapeutics Receives Revised Analyst Outlook Following Clinical Milestone
03.01.2026 - 14:52:05 | boerse-global.de
Shares of Capricor Therapeutics are undergoing a reassessment by market experts, reflecting a shift in sentiment. The biotech firm’s stock, which closed at $28.31 after a 1.91% decline on Friday, is navigating a period of significant market volatility.
The recent movement in Capricor’s valuation is anchored in promising data from its pivotal HOPE-3 Phase 3 trial. The company’s cell therapy, Deramiocel, designed to treat Duchenne Muscular Dystrophy, successfully met its primary endpoint. Results demonstrated a 54% reduction in disease progression compared to a placebo. A key secondary endpoint, measuring the decline in cardiac function, showed an even more substantial 91% improvement.
This clinical breakthrough has not gone unnoticed by major investors. Read more...
